Sort
82,697 grants matching “vaccine development”
Epigenetic Regulation of Normal and Pathologic CTCF Functions by BORIS
$804,869Victor Lobanenkov · Niaid Extramural Activities · Z01 · FY2007 · AI
Statistical Issues in AIDS Research
$804,814James P Hughes · University Of Washington · R37 · FY2025 · AI
Role of B Lymphocytes In HIV Infection And Pathogenesis
$804,809Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Novel Methods to Inform HIV/TB Clinical Trial Development
$804,735Krishna P Reddy · Massachusetts General Hospital · R01 · FY2021 · AI
Containing Bioterrorist and Emerging Infectious Diseases
$804,631M Elizabeth Halloran · Fred Hutchinson Cancer Research Center · U01 · FY2012 · GM
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
$804,593Mark Joseph Mulligan · New York University School Of Medicine · UM1 · FY2024 · AI
Design Of Immunogens
$804,553Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Design Of Immunogens
$804,553Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Design Of Immunogens
$804,553Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Impact of eliminating nonmedical exemptions in California
$804,465Saad B. Omer · Yale University · R01 · FY2019 · AI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design
$804,299George M Shaw · University Of Pennsylvania · R01 · FY2022 · AI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies
$804,299George M Shaw · University Of Pennsylvania · R01 · FY2022 · AI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design
$804,299George M Shaw · University Of Pennsylvania · R01 · FY2024 · AI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design
$804,299George M Shaw · University Of Pennsylvania · R01 · FY2023 · AI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies
$804,299George M Shaw · University Of Pennsylvania · R01 · FY2024 · AI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies
$804,299George M Shaw · University Of Pennsylvania · R01 · FY2025 · AI
Development of a Universal Immunotherapeutic for Influenza Viruses
$804,193Frederick Wayne Holtsberg · Integrated Biotherapeutics, Inc. · R44 · FY2021 · AI
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$804,182Univ Of Massachusetts Med Sch Worcester · U01 · FY2000 · AI
Expanded Phase II Trial of Carraguard for Prevention of HPV Infection
$804,139Mark H. Einstein · Albert Einstein College Of Medicine · R01 · FY2012 · CA
Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development
$804,081Thomas Denny · Duke University · N01 · FY2023 · AI
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$803,979Wesley C Van Voorhis · University Of Washington · R01 · FY2023 · AI
Novel Interventions Against HPV-associated Neoplasia
$803,955Paul F Lambert · University Of Wisconsin-Madison · U01 · FY2010 · CA
Optimization of Lead BKIs for Cryptosporidiosis Therapy
$803,939Wesley C Van Voorhis · University Of Washington · R01 · FY2024 · AI
Screening Complete TB Proteome for Protective Antigens
$803,880Alan Greener · Gene Therapy Systems, Inc. · R44 · FY2007 · AI
Correlates of protective immunity to HCV and rational vaccine design: Project 2
$803,843Arash Grakoui · Emory University · U19 · FY2024 · AI